logo
  • About
    • MNI Leadership Board
  • HCP Resources
    • Education
    • HCP Consensus Statements from CJON
    • HCP Toolkits
    • ctDNA Testing for Response Monitoring
    • BRAF Testing
    • Care Step Pathways
    • Facebook Q&A Community
  • Videos
    • HCP Videos
    • Patient Videos
  • Decision Support Tools
    • Options for Stage II Melanoma
    • Options for Stage III Melanoma
    • Options for Stage IV Melanoma
  • Patient Resources
    • Patient Action Plans
    • Non-Invasive Evaluation Tools For Suspicious Spots
    • TIL Therapy
    • Side Effect Search
    • BRAF Q&A
    • ctDNA Testing Handout
    • Oncolytic Viruses
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • About
    • MNI Leadership Board
  • HCP Resources
    • Education
    • HCP Consensus Statements from CJON
    • HCP Toolkits
    • ctDNA Testing for Response Monitoring
    • BRAF Testing
    • Care Step Pathways
    • Facebook Q&A Community
  • Videos
    • HCP Videos
    • Patient Videos
  • Decision Support Tools
    • Options for Stage II Melanoma
    • Options for Stage III Melanoma
    • Options for Stage IV Melanoma
  • Patient Resources
    • Patient Action Plans
    • Non-Invasive Evaluation Tools For Suspicious Spots
    • TIL Therapy
    • Side Effect Search
    • BRAF Q&A
    • ctDNA Testing Handout
    • Oncolytic Viruses
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK

The Melanoma Nursing Initiative – Home › Forums › Targeted therapy

  • This category has 12 topics, 43 replies, and was last updated October 28, 2018 at 9:00 am by Mandi Murph.
    • Forum
    • Topics
    • Posts
    • Last Post
    • Expectations for therapy
    • 1
    • 2
    • Reply To: Targeted therapies for adjuvant therapy

      November 3, 2017 at 2:07 am

      Anonymous

    • Dosing and administration
    • 2
    • 18
    • Reply To: New BRAF/MEK inhibitors coming to market

      October 8, 2018 at 10:07 am

      Anonymous

    • Side-effect management
    • 2
    • 9
    • Reply To: Fevers

      October 28, 2018 at 9:00 am

      Mandi Murph

    • Reimbursement
    • 0
    • 0
    • December 8, 2017 at 4:58 pm

      Anonymous

    • Other
    • 7
    • 26
    • Reply To: Variants to mutations; fusions and

      June 25, 2018 at 8:58 am

      Anonymous

  •  

Login

Log In
Register Lost Password

Latest Activity

  • Immunotherapy in Hepatitis B carriers
    topic by Anonymous
    February 25
    in Other
  • Esophagitis
    reply by Anonymous
    February 18
    in Side-effect management
  • mucositis & mouth sores from Nivo
    reply by Mandi Murph
    January 27
    in Side-effect management
  • Immunotherapy and Solid organ transplant
    reply by Anonymous
    January 23
    in Other
  • Nivolumab dilution
    reply by Mandi Murph
    November 18
    in Dosing and administration
Copyright ©2023- - The Melanoma Nursing Initiative. All rights reserved.
  • Terms
  • Privacy
  • News
  • Contact